The
Army Distaff Foundation (ADF), a non-profit
charity in Washington, D.C., which operates Knollwood Military Life
Plan Community, is the first life plan community to adopt the
use of Ekso Bionics’ (Nasdaq: EKSO) robotic exoskeleton for
rehabilitation with aging adult populations.
As part of its comprehensive fall prevention program, ADF has
invested in and implemented new technology and innovation like the
EksoGT exoskeleton device. The exoskeleton is designed to help
patients stand and walk during physical therapy after a stroke,
acquired brain injury, or spinal cord injury.
Through the program, ADF began trialing the use of EksoGT for
rehabilitation with older adults at Knollwood in February 2018.
Thirty people completed the EksoGT therapy, which has improved
gait, balance, strength and mobility, contributing to fewer falls,
according to ADF.
“The military has long been a leader and early adopter of
technology, from the creation of the internet to satellites and
GPS,” said Major General (USA, Ret.) Timothy P. McHale, President
and CEO of ADF. As was recently featured on the cover of
TIME Magazine in November of 2019, “ADF is
pioneering the use of numerous technologies, including an
Artificial Intelligence-enabled robot designed to engage its
residents socially, a COVID-19 Lab and Testing Center, a UV-light
disinfection system, integrative cognitive therapies that improve
brain health, and an innovative fall prevention program with
in-home lighting and monitoring systems. The adoption of the EksoGT
robotic exoskeleton was a natural choice for providing
technology-enhanced health care in our community.”
ADF provides the full continuum of care to adults as they age.
It offers its 300 residents the option of independent living,
assisted living, long-term care, skilled nursing, rehabilitation,
memory support, and hospice care.
ADF’s extensive rehabilitation programs harness the use of the
latest technologies to help older adults with their recovery.
“Because falls are especially devastating among older adults,
causing over 90% of hip and wrist fractures and 60% of head
injuries, ADF has invested in and implemented a comprehensive fall
prevention program that embraces technology and innovation,” said
Adriana Winters, RPT, Rehabilitation Services Director. “Our trial
of the EksoGT demonstrated to us that rehabilitation with this
exoskeleton device can help older adults regain mobility and
independence as they relearn to walk after a stroke or another
injury. They experienced improved functional strength, improved
gait, and regained independence which kept them motivated. We’re
pleased to begin offering exoskeleton-assisted rehabilitation more
widely.”
EksoGT is the most clinically used robotic exoskeleton globally
and has helped patients take more than 120 million steps.
“It is no surprise that tech-savvy organizations like ADF are
embracing the use of exoskeletons for rehabilitation, but it is
particularly exciting that they are the first continuing care
retirement community to bring this technology to its residents and
patients,” said Jack Peurach, Chief Executive Officer and President
of Ekso Bionics. “ADF’s commitment to supporting older adults
living engaged, purposeful lives, is further underscored with
EksoGT in rehabilitation programs that are improving patient
recovery.”
About Army Distaff FoundationThe Army Distaff
Foundation (ADF) is a 501(c)(3) organization established in 1959
that provides a compassionate community with exceptional wellness
care and purposeful living for older adults who served our nation.
People enjoy vibrant community living, robust wellness programs to
suit all interests, and the most cutting-edge application of
technology and innovative health and wellness programs. ADF serves
as a model that inspires other communities nationwide by its
excellent example. For more information,
visit: armydistaff.org.
About Ekso Bionics® Ekso Bionics® is
a leading developer of exoskeleton solutions that amplify human
potential by supporting or enhancing strength, endurance and
mobility across medical and industrial applications. Founded in
2005, the Company continues to build upon its industry-leading
expertise to design some of the most cutting-edge, innovative
wearable robots available on the market. Ekso Bionics is the only
exoskeleton company to offer technologies that range from helping
those with paralysis to stand up and walk, to enhancing human
capabilities on job sites across the globe. The Company is
headquartered in the San Francisco Bay Area and is listed on the
Nasdaq Capital Market under the symbol “EKSO.” For more
information,
visit: www.eksobionics.com or follow
@EksoBionics on Twitter.
Forward-Looking StatementsAny statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements. Forward-looking
statements may include, without limitation, statements regarding
(i) the potential benefits of the Company’s products, including the
EksoGT, (ii) the performance or effectiveness of the Company’s
products, including the EksoGT, and (iii) the assumptions
underlying or relating to any statement described in clauses (i)
and (ii) above. Such forward-looking statements are not meant to
predict or guarantee actual results, performance, events or
circumstances and may not be realized because they are based upon
the Company’s current projections, plans, objectives, beliefs,
expectations, estimates and assumptions and are subject to a number
of risks and uncertainties and other influences, many of which the
Company has no control over. Actual results and the timing of
certain events and circumstances may differ materially from those
described by the forward-looking statements as a result of these
risks and uncertainties. Factors that may influence or contribute
to the inaccuracy of the forward-looking statements or cause actual
results to differ materially from expected or desired results may
include, without limitation, the Company’s inability to obtain
adequate financing to fund the Company’s operations and necessary
to develop or enhance the Company’s technology, the significant
length of time and resources associated with the development of the
Company’s products, the Company’s failure to achieve broad market
acceptance of the Company’s products, the failure of the Company’s
sales and marketing efforts or of partners to market the Company’s
products effectively, adverse results in future clinical studies of
the Company’s medical device products, the failure to obtain or
maintain patent protection for the Company’s technology, the
failure of the Company to obtain or maintain regulatory approval to
market the Company’s medical devices, the lack of product
diversification, existing or increased competition, and the
Company’s failure to implement the Company’s business plans or
strategies. These and other factors are identified and described in
more detail in the Company’s filings with the U.S. Securities and
Exchange Commission. To learn more about Ekso Bionics please visit
the Company’s website at www.eksobionics.com or follow @EksoBionics
on Twitter. The Company does not undertake to update these
forward-looking statements.
Media Contacts:Carrie Yamond
Mas917-371-2320cmas@eksobionics.com
Jim MichelsArmy Distaff
Foundation202-541-0492JMichels@armydistaff.org
Investor Contact:David
Carey212-867-1768investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Sep 2023 to Sep 2024